37527-48-3

Basic information

• Product Name: 6-CHLORO-7H-PURIN-8(9H)-ONE
• Synonyms: 6-CHLORO-7H-PURIN-8(9H)-ONE
• CAS NO: 37527-48-3
• Molecular Formula: C₅H₃ClN₄O
• Molecular Weight: 170.55652
• Mol File: 37527-48-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 2.09±0.1 g/cm3(Predicted)
• PKA: 6.42±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-7H-PURIN-8(9H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-7H-PURIN-8(9H)-ONE(37527-48-3)
• EPA Substance Registry System: 6-CHLORO-7H-PURIN-8(9H)-ONE(37527-48-3)

Safety Data

• Hazardous Substances Data: 37527-48-3(Hazardous Substances Data)

Usage

Description

6-CHLORO-7H-PURIN-8(9H)-ONE is an organic compound that serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the field of pharmaceuticals. It is characterized by its unique chemical structure, which includes a purine core with a chlorine atom at the 6th position and an 8(9H)-one functional group. This structure endows it with specific reactivity and properties that make it valuable in the development of therapeutic agents.

Uses

Used in Pharmaceutical Industry:
6-CHLORO-7H-PURIN-8(9H)-ONE is used as a synthetic intermediate for the preparation of metabolites of tri-O-acetyl-N6-(hydroxyphenyl)adenosine. These metabolites have potential applications in the development of new drugs targeting various diseases and conditions.
In the synthesis of biologically active molecules, 6-CHLORO-7H-PURIN-8(9H)-ONE is used as a building block for the creation of novel compounds with potential therapeutic properties. Its unique structure allows for further chemical modifications and functionalization, enabling the development of new drugs with improved efficacy and selectivity.
Additionally, 6-CHLORO-7H-PURIN-8(9H)-ONE may be utilized in the research and development of new drug candidates, particularly in the areas of oncology, virology, and immunology. Its reactivity and structural features make it a promising starting point for the design and synthesis of innovative therapeutic agents.

Upstream product

• 4316-98-7 6-chloro-4,5-diaminopyrimidine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 74124-79-1 di(succinimido) carbonate 
• 13231-00-0 diceto-6,8 purine 
• 19916-15-5 6,8-dichloro-7(9)H-purine 

Downstream Products

• 885595-03-9 6-(4-phenylacetylpiperidin-1-yl)-7,9-dihydropurin-8-one 

Relevant articles and documents

The synthesis of the metabolites of 21,31,51-Tri-O-acetyl-N6-(3-hydroxyphenyl) adenosine (WS070117)

Seven metabolites of 21,31,51-tri-O-acetyl-N6-(3-hydroxyphenyl) adenosine (WS070117) were synthesized by deacetylation, hydrolysis, cyclization, sulfonylation and glycosylation reactions, respectively. All these compounds, which could be useful as material standards for metabolic research, were characterized by NMR and HPLC-MS (ESI) analyses.

MORPHOLINO-SUBSTITUTED BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS ANTI CANCER AGENTS

The present invention pertains generally to the field of therapeutic compounds, and mor specifically to certain morpholino-substituted bicydoheteroaryl compounds (referred to herein as MBHA compounds), of the following formula: and especially certain morp

PHARMACEUTICAL COMPOUNDS

The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH2, O, S or NH and G is a C1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R1 is hydrogen or an aryl or heteroaryl group; R2 and R3 are each hydrogen, optionally substituted C1-4 hydrocarbyl or optionally substituted C1-4 acyl; or NR2R3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR2R3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C1-4 alkyl; or NR2R3 and the adjacent carbon atom of linker group A together form a cyano group; or R1, A and NR2R3 together form a cyano group; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen and various substituents as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated.